Modality
Fusion Protein
MOA
EZH2i
Target
FLT3
Pathway
Wnt
Bladder Ca
Development Pipeline
Preclinical
~May 2017
→ ~Aug 2018
Phase 1
~Nov 2018
→ ~Feb 2020
Phase 2
~May 2020
→ ~Aug 2021
Phase 3
Nov 2021
→ Aug 2030
Phase 3Current
NCT07085107
354 pts·Bladder Ca
2022-01→2027-01·Recruiting
NCT06977501
543 pts·Bladder Ca
2021-11→2030-08·Completed
NCT03358109
2,129 pts·Bladder Ca
2023-09→2025-05·Recruiting
3,026 total pts1 indication
NDA/BLA
Approved
CompletedCurrentUpcoming
Catalysts (3)
2025-05-1511mo agoPh3 Readout· Bladder Ca
2027-01-2810mo awayPh3 Readout· Bladder Ca
2030-08-064.4y awayPh3 Readout· Bladder Ca
Trial Timeline
Q42022Q2Q3Q42023Q2Q3Q42024Q2Q3Q42025Q2Q3Q42026Q2Q3Q42027Q2Q3Q42028Q2Q3Q42029Q2Q3Q42030Q2Q3Q4
P3
Complet…
P3
Recruit…
P3
Recruit…
Catalysts
Ph3 Readout
2025-05-15 · 11mo ago
Bladder Ca
Ph3 Readout
2027-01-28 · 10mo away
Bladder Ca
Ph3 Readout
2030-08-06 · 4.4y away
Bladder Ca
RecruitingCompleted|StartCompletionToday
Trials (3)
| NCT | Phase | Indication | Status | N | EP |
|---|---|---|---|---|---|
| NCT07085107 | Phase 3 | Bladder Ca | Recruiting | 354 | LiverFat |
| NCT06977501 | Phase 3 | Bladder Ca | Completed | 543 | HAM-D |
| NCT03358109 | Phase 3 | Bladder Ca | Recruiting | 2129 | CR |
Competitors (10)
| Drug | Company | Phase | Target | MOA |
|---|---|---|---|---|
| JNJ-8168 | Johnson & Johnson | Phase 2/3 | FLT3 | |
| Adagrazumab | Novartis | Phase 2/3 | Cl18.2 | |
| Ribotuximab | Merck & Co | Phase 2 | GPRC5D | |
| NVO-9615 | Novo Nordisk | Phase 2/3 | PRMT5 | |
| Sotorapivir | Moderna | Approved | FLT3 | |
| Nidaratamab | Exelixis | Phase 3 | FLT3 | |
| Polalucimab | Jazz Pharma | Preclinical | PLK4 | |
| ASN-7038 | Ascendis Pharma | Phase 3 | VEGF | |
| Liratinib | Krystal Biotech | NDA/BLA | TIM-3 | |
| Zanumavacamten | Iovance | Phase 2 | FLT3 |